semaglutide and dapagliflozin combination Randomized open-label trial of in patients with type 2 diabetes of different pathophysiology Randomized open-label trial of semaglutide
Description
Date: 25 December 2024) Consent to publish Not applicable
Am J Physiol Regul Integr Comp Physiol 290:R1728-1735
Zepbound (tirzepatide) Zepbound is a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist
On the weight-worsening-fibromyalgia side: increased mechanical load on muscles and joints increases pain signals
If you are also taking diabetes medications such as insulin or sulfonylureas, the combined effect may cause your blood sugar to dip too low
